BioSpace News Archive

New England Biolabs (NEB®), a leading supplier of reagents for the life sciences, today announced the launch of a web-based tool for monitoring the emergence of SARS-CoV-2 variants and their potential impact on COVID-19 diagnostic tests.

Bexson Biomedical, Inc. will present details on its R&D pipeline and give a corporate update at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Conference on June 17th.

NYU Langone Health has been selected as the Clinical Science Core for the National Institutes of Health’s PASC Initiative. In this role, the CSC could potentially receive up to $52 million over the full funding period to lead and integrate the research activities of clinical sites around the country studying the long-term effects of SARS-CoV-2 infection.

Akoya Biosciences Inc., announced today that its Phenoptics solution contributed to the successful development of a novel platform, titled AstroPath.

Neovasc Inc. announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024, focusing investments on near term value drivers, and more deeply reviewing the Company’s core business activities.

Biogen Inc. (Nasdaq: BIIB) announced today that it will hold an Investor Day focused on its broad pipeline across neuroscience and related therapeutic adjacencies.

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors, announced financial results for its fourth quarter and fiscal year ended March 31, 2021.

The global biostimulants market size is expected to reach USD 6.75 billion in 2028 and register a CAGR of 11.3%, according to the latest report by Reports and Data.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in a Phase 2 proof-of-concept study, VX-864 achieved rapid, consistent and statistically significant increases in mean functional alpha-1 antitrypsin (fAAT) levels of 2.2 to 2.3 micromolar from baseline in people with alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype, across three dose groups of VX-864 compared to placebo

Rising prevalence of Alzheimer’s disease, epilepsy, Parkinson’s disease, development of customized antibodies in precision medicine, and advancements in neuroscience research are key factors driving market growth.